An employee works at the Covid-19 vaccine trial production workshop at Livzon Pharmaceutical Group Inc in south China's Guangdong Province. - Xinhua
GUANGZHOU, Aug 30 (Xinhua): A recombinant Covid-19 fusion protein vaccine (V-01) developed and manufactured in China has been approved for phase-III clinical trials in the Philippines.
The V-01 vaccine was developed by the Institute of Biophysics under the Chinese Academy of Sciences and Livzon Pharmaceutical Group Inc. (LivzonBio) in south China's Guangdong Province.
Already a subscriber? Log in
Save 30% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
